Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

[A comparison analysis of the use of intravenous β-interferon-1a 30 mcg and subcutaneous β-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis].
The American Academy of Neurology's Top Five Choosing Wisely recommendations.
Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis
Early Growth Response Gene-2 Controls IL-17 Expression and Th17 Differentiation by Negatively Regulating Batf.
Transverse myelitis -- a review of the presentation, diagnosis, and initial management.
Novel Immune Regulator Shows Promise as MS Therapy in Clinical Trials
Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis.
lipid-specific IgM bands in csf associated with a reduced risk of developing pml during treatment with natalizumab.
Metabolic features of the cell danger response.
SMC Says Yes to Lemtrada(R)a- 1/4 (alemtuzumab) 12mg IV, a New Treatment for Adults with Active Relapsing Remitting-Multiple Sclerosis (RRMS)
Possible pathogenic engagement of soluble Semaphorin 4D produced by γδT cells in medication-related osteonecrosis of the jaw (MRONJ).
Helminth therapy and multiple sclerosis.
Early signs of memory impairment among multiple sclerosis patients with clinically isolated syndrome.
Neuromyelitis optica spectrum disorder: 2-deoxy-2-[(18)f]fluoro-d-glucose positron emission tomography findings.
Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study.
Health Canada Approves PLEGRIDY™ (peginterferon beta-1a) for Adults with Relapsing Remitting Multiple Sclerosis
Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.
Overcoming barriers in progressive multiple sclerosis research.
"Undiagnosing" multiple sclerosis: The challenge of misdiagnosis in MS.
High-field imaging of neurodegenerative diseases.
Treatment of multiple sclerosis with anti-CD20 antibodies.
A Herpes Simplex Virus-Derived Replicative Vector Expressing LIF Limits Experimental Demyelinating Disease and Modulates Autoimmunity.
A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging.

Pages